Rho C Inhibitors
Rho C inhibitors represent a diverse class of chemical compounds designed to interfere with the signaling pathways governed by the RhoC GTPase, a key regulator of cellular motility and invasion. These inhibitors can be broadly categorized into direct and indirect inhibitors, each with distinct mechanisms of action. Direct inhibitors such as Rhosin, CCG-1423, and Y-27632 target RhoC itself, disrupting its interaction with downstream effectors. Rhosin, for example, impedes the binding of RhoC to ROCK, modulating actin cytoskeleton dynamics and cellular motility. CCG-1423 specifically inhibits the Rho/MRTF/SRF pathway, suppressing the nuclear translocation of MRTF and the subsequent activation of SRF.
Indirect inhibitors, exemplified by compounds like IWR-1-endo and Secramine A, interfere with RhoC-mediated processes by targeting interconnected signaling pathways. IWR-1-endo, an antagonist of the Wnt pathway, indirectly influences RhoC by disrupting the cross-talk between Wnt and Rho signaling. Secramine A, although targeting Cdc42, indirectly impacts RhoC-related pathways involved in cytoskeletal dynamics and cellular motility. These diverse inhibitors collectively provide a comprehensive toolbox for researchers aiming to dissect the intricacies of RhoC-mediated cellular processes. In summary, RhoC inhibitors offer precise tools for studying and modulating cellular motility, particularly in the context of cancer metastasis. The direct and indirect mechanisms of action showcased by these inhibitors highlight the intricate web of signaling pathways and molecular interactions that contribute to RhoC-mediated processes, providing avenues for targeted pharmacological interventions in cancer research and beyond.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
CCG-1423 is a chemical compound recognized for its inhibitory action on Rho signaling. Functioning as a direct inhibitor of the Rho/MRTF/SRF pathway, CCG-1423 hinders the nuclear translocation of MRTF (Myocardin-Related Transcription Factor), consequently attenuating the activation of serum response factor (SRF). By disrupting this pathway, CCG-1423 impedes the expression of genes associated with cellular motility and invasion. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a well-established Rho-associated protein kinase (ROCK) inhibitor. It exerts its inhibitory effects by blocking the ATP-binding site of ROCK, leading to reduced phosphorylation of downstream targets. In the context of RhoC, Y-27632 disrupts the RhoC/ROCK axis, thereby inhibiting actomyosin contractility and modulating cellular motility | ||||||
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $135.00 | 19 | |
IWR-1-endo is a chemical inhibitor known for its antagonistic action on the Wnt signaling pathway. While not directly targeting RhoC, IWR-1-endo indirectly influences RhoC-mediated processes by inhibiting the canonical Wnt pathway. Wnt signaling is interconnected with Rho GTPases, and IWR-1-endo's interference with this pathway can lead to downstream effects on RhoC activity. | ||||||
IPA 3 | 42521-82-4 | sc-204016 sc-204016A | 5 mg 50 mg | $94.00 $458.00 | 6 | |
IPA-3 is an inhibitor that targets PAK1, a downstream effector of the Rho family GTPases, including RhoC. By inhibiting PAK1, IPA-3 disrupts the downstream signaling cascades involved in cellular motility and cytoskeletal dynamics. While not directly targeting RhoC, IPA-3's action on a key effector in the Rho signaling pathway highlights an alternative approach to modulating RhoC-mediated processes. | ||||||
AZA1 | 1071098-42-4 | sc-507497 | 10 mg | $600.00 | ||
AZA1 is a small molecule inhibitor that disrupts the interaction between RhoA and its downstream effector mDia1. Although primarily targeting RhoA, AZA1's action on a downstream effector shared with RhoC suggests a potential indirect modulation of RhoC-mediated processes. | ||||||
Rhosin | 1173671-63-0 | sc-507401 | 25 mg | $555.00 | ||
Rhosin hydrobromide is a hydrobromide salt form of Rhosin, a RhoC inhibitor. Similar to Rhosin, it disrupts the interaction between RhoC and ROCK, leading to the inhibition of downstream signaling cascades. | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $321.00 $1040.00 | 5 | |
CK-666 is a chemical compound recognized for its inhibitory activity against the Arp2/3 complex, a regulator of actin polymerization. While not directly targeting RhoC, CK-666 indirectly influences RhoC-mediated processes by inhibiting actin dynamics. The Arp2/3 complex is involved in the formation of actin branches, a process essential for cellular motility. | ||||||